{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-272557","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.658287+00:00","generated_at":"2026-06-08T16:59:04.027365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biote Q3 revenue $45.6M (+8.5% YoY); net income $19.6M; Adj. EBITDA $14.0M","bullets":["Revenue $45.6M (+8.5% YoY) driven by procedure revenue growth of 7.4% and supplement growth of 5.1%.","Net income $19.6M (43.1% margin) vs $0.5M in prior year; basic EPS $0.25 vs $0.00.","Adjusted EBITDA $14.0M (+14.7% YoY); margin 30.8% (+165bps).","Reiterated FY2023 guidance: revenue $190-200M, Adj. EBITDA $56-60M; expects lower end.","Progress in commercial trials of complementary wellness therapeutics (sexual health, weight loss, preventive)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-272557","json":"https://secwatch.observer/filing/0001193125-23-272557.json","markdown":"https://secwatch.observer/filing/0001193125-23-272557.md","text":"https://secwatch.observer/filing/0001193125-23-272557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523272557/0001193125-23-272557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523272557/d908833d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T16:59:04.027365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b35e0f0e8d1e0abebc9dcd79e9ef7bd3826bbb0e","claim":"biote Corp. reported the third quarter ended September 30, 2023 results: revenue $45.6 million, net income $19.6 million, EPS $0.25 per basic share. Guidance reaffirmed.","evidence_excerpt":"for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) • Revenue of $45.6 million, an 8.5% increase • Gross profit margin of 68.9%, a 70-basis point increase • Net income of $19.6 million, representing net income margin of 43.1%, and basic earnings per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523272557/0001193125-23-272557-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$45.6 million"},{"label":"Net income","value":"$19.6 million"},{"label":"EPS","value":"$0.25 per basic share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}